Mesalamine (Lialda) vs olsalazine (Dipentum)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Ulcerative Colitis

Shared mechanism: Aminosalicylate · full Ulcerative Colitis pipeline

Mesalamine (Lialda)

Marketed by Takeda Pharmaceutical Company and partners

Approved in Ulcerative Colitissmall molecule
Reliable signal

NCT00151892 · Phase 3 · completed

This was a randomized, quadruple-blind, active-controlled trial with 829 participants and an objective endoscopic primary endpoint. Lialda was non-inferior to Asacol for six-month endoscopic remission: 83.7% versus 81.5%, with the 95% confidence interval for the difference (-4% to 8%) remaining within the prespecified -10% margin.

Reported efficacy

Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months: Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants (met)

Result source: NCT00151892

olsalazine (Dipentum)

Marketed by Viatris

Approved in Ulcerative Colitissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Ulcerative Colitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointMesalamine (Lialda)olsalazine (Dipentum)
Clinical remission (induction)—Not posted · NCT00548574—Not reported
Clinical remission (maintenance)—Not posted · NCT00548574—Not reported
Clinical response (induction)—Not posted · NCT00548574—Not reported
Endoscopic improvement (induction)—Not posted · NCT00548574—Not reported
Corticosteroid-free remission (maintenance)—Not posted · NCT00548574—Not reported

Clinical remission (induction)

Mesalamine (Lialda)
—Not posted · NCT00548574
olsalazine (Dipentum)
—Not reported

Clinical remission (maintenance)

Mesalamine (Lialda)
—Not posted · NCT00548574
olsalazine (Dipentum)
—Not reported

Clinical response (induction)

Mesalamine (Lialda)
—Not posted · NCT00548574
olsalazine (Dipentum)
—Not reported

Endoscopic improvement (induction)

Mesalamine (Lialda)
—Not posted · NCT00548574
olsalazine (Dipentum)
—Not reported

Corticosteroid-free remission (maintenance)

Mesalamine (Lialda)
—Not posted · NCT00548574
olsalazine (Dipentum)
—Not reported
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

olsalazine (Dipentum): no structured comparison results are available for Ulcerative Colitis.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Mesalamine (Lialda)
Endoscopic Remission of Ulcerative Colitis (UC) at 6 Months (6 Months): SPD476 83.7 percent of participants | Asacol 81.5 percent of participants NCT00151892 · Phase 3 · design grade: strong · reviewed ClinicalTrials.gov result

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Mesalamine (Lialda)'s landscape · olsalazine (Dipentum)'s landscape